Literature DB >> 15069706

Comparison of conformal and intensity-modulated techniques for simultaneous integrated boost radiotherapy of upper esophageal carcinoma.

Wei-Hua Fu1, Lu-Hua Wang, Zong-Mei Zhou, Jian-Rong Dai, Yi-Min Hu, Lu-Jun Zhao.   

Abstract

AIM: To compare intensity-modulated radiotherapy (IMRT) with conformal radiotherapy (CRT) by investigating the dose profiles of primary tumors, electively treated regions, and the doses to organs at risk.
METHODS: CRT and IMRT plans were designed for five patients with upper esophageal carcinoma. For each patient, target volumes for primary lesions (67.2 Gy) and electively treated regions (50.4 Gy) were predefined. An experienced planner manually designed one CRT plan. Four IMRT plans were generated with the same dose-volume constraints, but with different beam arrangements. Indices including dose distributions, dose volume histograms (DVHs) and conformity index were compared.
RESULTS: The plans with three intensity-modulated beams were discarded because the doses to spinal cord were lager than the tolerable dose 45Gy, and the dose on areas near the skin was up to 50Gy. When the number of intensity beams increased to five, IMRT plans were better than CRT plans in terms of the dose conformity and homogeneity of targets and the dose to OARs. The dose distributions changed little when the beam number increased from five to seven and nine.
CONCLUSION: IMRT is superior to CRT for the treatment of upper esophageal carcinoma with simultaneous integrated boost (SIB). Five equispaced coplanar intensity-modulated beams can produce desirable dose distributions. The primary tumor can get higher equivalent dose by SIB technique. The SIB-IMRT technique shortens the total treatment time, and is an easier, more efficient, and perhaps a less error-prone way in delivering IMRT.

Entities:  

Mesh:

Year:  2004        PMID: 15069706      PMCID: PMC4656341          DOI: 10.3748/wjg.v10.i8.1098

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  28 in total

1.  Intensity-modulated tangential beam irradiation of the intact breast.

Authors:  L Hong; M Hunt; C Chui; S Spirou; K Forster; H Lee; J Yahalom; G J Kutcher; B McCormick
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-07-15       Impact factor: 7.038

2.  Treatment planning and delivery of intensity-modulated radiation therapy for primary nasopharynx cancer.

Authors:  M A Hunt; M J Zelefsky; S Wolden; C S Chui; T LoSasso; K Rosenzweig; L Chong; S V Spirou; L Fromme; M Lumley; H A Amols; C C Ling; S A Leibel
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

3.  Radiotherapy of double primary esophageal carcinoma.

Authors:  Ze-Fen Xiao; Zong-Yi Yang; Zong-Mei Zhou; Wei-Bo Yin; Xian-Zhi Gu
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

4.  Dose optimization for the treatment of anaplastic thyroid carcinoma: a comparison of treatment planning techniques.

Authors:  M D Posner; J M Quivey; P F Akazawa; P Xia; C Akazawa; L J Verhey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-09-01       Impact factor: 7.038

5.  Radiotherapy of prostate cancer with or without intensity modulated beams: a planning comparison.

Authors:  G O De Meerleer; L A Vakaet; W R De Gersem; C De Wagter; B De Naeyer; W De Neve
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-06-01       Impact factor: 7.038

6.  The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: a treatment design study.

Authors:  Q Wu; M Manning; R Schmidt-Ullrich; R Mohan
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-01-01       Impact factor: 7.038

7.  A conformation number to quantify the degree of conformality in brachytherapy and external beam irradiation: application to the prostate.

Authors:  A van't Riet; A C Mak; M A Moerland; L H Elders; W van der Zee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-02-01       Impact factor: 7.038

8.  Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer.

Authors:  M J Zelefsky; Z Fuks; L Happersett; H J Lee; C C Ling; C M Burman; M Hunt; T Wolfe; E S Venkatraman; A Jackson; M Skwarchuk; S A Leibel
Journal:  Radiother Oncol       Date:  2000-06       Impact factor: 6.280

9.  Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma.

Authors:  David Huang; Ping Xia; Pam Akazawa; Clayton Akazawa; Jeanne M Quivey; Lynn J Verhey; Michael Kaplan; Nancy Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-05-01       Impact factor: 7.038

10.  Intensity-modulated radiotherapy versus conventional three-dimensional conformal radiotherapy for boost or salvage treatment of nasopharyngeal carcinoma.

Authors:  Ching-Yeh Hsiung; Ellen D Yorke; Chen-Shou Chui; Margie A Hunt; Clifton C Ling; Eng-Yen Huang; Chong-Jong Wang; Hui-Chun Chen; Shyh-An Yeh; Hsuan-Chih Hsu; Howard I Amols
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-07-01       Impact factor: 7.038

View more
  14 in total

Review 1.  Technological advances in radiotherapy for esophageal cancer.

Authors:  Milan Vosmik; Jiri Petera; Igor Sirak; Miroslav Hodek; Petr Paluska; Jiri Dolezal; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

2.  Reference values for craniofacial structures in children 4 to 6 years old: review of the literature.

Authors:  Mirjam Hönn; Gernot Göz
Journal:  J Orofac Orthop       Date:  2007-05       Impact factor: 1.938

3.  Simultaneous integrated boost intensity-modulated radiotherapy in esophageal carcinoma: early results of a phase II study.

Authors:  Wei-Wei Yu; Zheng-Fei Zhu; Xiao-Long Fu; Kuai-Le Zhao; Jing-Fang Mao; Kai-Liang Wu; Huan-Jun Yang; Min Fan; Sen Zhao; James Welsh
Journal:  Strahlenther Onkol       Date:  2014-03-08       Impact factor: 3.621

4.  High FDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer.

Authors:  Jérémie Calais; Bernard Dubray; Lamyaa Nkhali; Sebastien Thureau; Charles Lemarignier; Romain Modzelewski; Isabelle Gardin; Frederic Di Fiore; Pierre Michel; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-14       Impact factor: 9.236

5.  Is dose escalation achievable for esophageal carcinoma?

Authors:  Laure Vieillevigne; Marie Vidal; Françoise Izar; Michel Rives
Journal:  Rep Pract Oncol Radiother       Date:  2015-01-05

6.  Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.

Authors:  Shu-Lian Wang; Zhongxing Liao; Helen Liu; Jaffer Ajani; Stephen Swisher; James D Cox; Ritsuko Komaki
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

7.  Effect of SIB-IMRT-based selective dose escalation of local tumor on the prognosis of patients with esophageal cancer.

Authors:  Hong-Mei Gao; Wen-Bin Shen; Jin-Rui Xu; You-Mei Li; Shu-Guang Li; Shu-Chai Zhu
Journal:  Int J Clin Oncol       Date:  2021-05-27       Impact factor: 3.402

Review 8.  Intensity-modulated radiation therapy for gastrointestinal tumors.

Authors:  Jeffrey J Meyer; Brian G Czito; Christopher G Willett
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

9.  Principles of modern radiation techniques for esophageal and gastroesophageal junction cancers.

Authors:  Gary Y Yang; Susan A McClosky; Nikhil I Khushalani
Journal:  Gastrointest Cancer Res       Date:  2009-03

10.  Definitive Simultaneous Integrated Boost Versus Conventional-Fractionated Intensity Modulated Radiotherapy for Patients With Advanced Esophageal Squamous Cell Carcinoma: A Propensity Score-Matched Analysis.

Authors:  Chen Li; Lijun Tan; Xiao Liu; Xin Wang; Zongmei Zhou; Dongfu Chen; Qinfu Feng; Jun Liang; Jima Lv; Xiaozhen Wang; Nan Bi; Lei Deng; Wenqing Wang; Tao Zhang; Wenjie Ni; Xiao Chang; Weiming Han; Zefen Xiao
Journal:  Front Oncol       Date:  2021-06-21       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.